The DOI matches its Crossref record; 366 of the 371 references it cites were found in a registry or an index.
EASL Clinical Practice Guidelines: Drug-induced liver injury
Abstract
Idiosyncratic (unpredictable) drug-induced liver injury is one of the most challenging liver disorders faced by hepatologists, because of the myriad of drugs used in clinical practice, available herbs and dietary supplements with hepatotoxic potential, the ability of the condition to present with a variety of clinical and pathological phenotypes and the current absence of specific biomarkers. This makes the diagnosis of drug-induced liver injury an uncertain process, requiring a high degree of awareness of the condition and the careful exclusion of alternative aetiologies of liver disease. Idiosyncratic hepatotoxicity can be severe, leading to a particularly serious variety of acute liver failure for which no effective therapy has yet been developed. These Clinical Practice Guidelines summarize the available evidence on risk factors, diagnosis, management and risk minimization strategies for drug-induced liver jury.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Drug-induced liver injury (DILI) is an uncommon adverse reaction to drugs, and other chemicals, including herbal and dietary supplements (HDS).”
From DILI Differences and Similarities between the US and Europe (2026) · cites this paper as [2]
In the citing paper
“The vast majority of cases of DILI occur at therapeutic doses in a small proportion of individuals exposed to the drug, representing an idiosyncratic reaction, and therefore unpredictable based on the drug's mechanism of action and related to the uniqueness of the individual [1,2].”
From DILI Differences and Similarities between the US and Europe (2026) · cites this paper as [2]
In the citing paper
“In pediatric medicine, DILI is a rare clinical situation. However, it has high morbidity and mortality, and it is one of the most common causes of acute liver failure. Furthermore, its diagnosis is clinically challenging due to its low incidence and phenotypic variability [6,7,8].”
From Metabolomic Analysis of Pediatric Patients with Idiosyncratic Drug-Induced Liver Injury According to the Updated RUCAM (2023) · cites this paper as [7]
In the citing paper
“The lack of a reliable diagnostic biomarker and evidence-based treatment paradigm has resulted in limited guidance on how to manage this aspect of DILI.”
From Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report (2023) · cites this paper as [2]
In the citing paper
“The lack of reliable diagnostic biomarkers and an evidence-based treatment paradigm has resulted in limited guidance on how to manage this aspect of DILI.2,25–27”
From Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report (2023) · cites this paper as [2]
In the citing paper
“However, drug rechallenge in DILI cases is potentially dangerous2,75 and is associated with risk of death or requirement for liver transplant.”
From Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report (2023) · cites this paper as [2]
In the citing paper
“Although there are some ambiguities regarding how to score certain sections as well as suboptimal reliability, RUCAM can provide systematic and framed guidance for the assessment of patients with suspected DILI and is the most widely used tool [26,27,51,59].”
From Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update (2024) · cites this paper as [26]
In the citing paper
“High TBil and ALP levels in the second month after an acute DILI episode and the biochemical nonresolution-6 model may help predict the risk of chronic injury and delayed recovery [26,72].”
From Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update (2024) · cites this paper as [26]
In the citing paper
“Although there are some ambiguities regarding how to score certain sections as well as suboptimal reliability, RUCAM can provide systematic and framed guidance for the assessment of patients with suspected DILI and is the most widely used tool [26,27,51,59].”
From Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update (2024) · cites this paper as [26]
In the citing paper
“Its potential value in confirming or excluding hepatocellular injury in cases of elevated ALT levels from a suspected extrahepatic origin (e.g., muscle) has been evaluated [26,175].”
From Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update (2024) · cites this paper as [26]
Citations
Cites
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
El-Khoueiry, A. B., Sangro, B., Yau, T., Crocenzi, T. S., Kudo, M., Hsu, C., Kim, T.-Y., Choo, S.-P., Trojan, J., Welling, T. H., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31046-2 · Cited by 4,280
Ekor, M. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00177 · Cited by 3,919
Alvarez, F., Berg, P. A., Bianchi, F. B., Bianchi, L., Burroughs, A. K., Cancado, E. L., Chapman, R. W., Cooksley, W. G. E., Czaja, A. J., Desmet, V. J., et al. (1999) · Journal of Hepatology · doi:10.1016/s0168-8278(99)80297-9 · Cited by 2,903
The influence of drug-like concepts on decision-making in medicinal chemistry
Leeson, P. D., & Springthorpe, B. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2445 · Cited by 2,403
Haanen, J. B. A. G., Carbonnel, F., Robert, C., Kerr, K. M., Peters, S., Larkin, J., & Jordan, K. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx225 · Cited by 2,367
Ostapowicz, G., Fontana, R. J., Schiødt, F. V., Larson, A., Davern, T. J., Han, S. H. B., McCashland, T. M., Shakil, A. O., Hay, J. E., Hynan, L., et al. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-12-200212170-00007 · Cited by 2,227
Immune-related adverse events with immune checkpoint blockade: a comprehensive review
Michot, J. M., Bigenwald, C., Champiat, S., Collins, M., Carbonnel, F., Postel-Vinay, S., Berdelou, A., Varga, A., Bahleda, R., Hollebecque, A., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2015.11.016 · Cited by 2,127
Acetaminophen‐induced acute liver failure
Larson, A. M., Polson, J., Fontana, R. J., Davern, T. J., Lalani, E., Hynan, L. S., REISCH, J. S., Schiødt, F. V., Ostapowicz, G., Shakil, A. O., et al. (2005) · Hepatology · doi:10.1002/hep.20948 · Cited by 1,913
Simplified criteria for the diagnosis of autoimmune hepatitis
Hennes, E. M., Zeniya, M., Czaja, A. J., Parés, A., Dalekos, G. N., Krawitt, E. L., Bittencourt, P. L., Porta, G., Boberg, K. M., Hofer, H., et al. (2008) · Hepatology · doi:10.1002/hep.22322 · Cited by 1,901
Flagged first, then by citations
5 of the 371 references couldn’t be matched to a known paper.
Research works printed but not linked: 5
- Nicoletti, 2017, Genome-wide association study (GWAS) to identify genetic risk factors that increase susceptibility to antituberculosis drug-induced liver injury (ATDILI) [Abstract], Hepatology, 66, A-25
- Lim, 2008, Association of HLA-B*1502 allele and carbamazepine-induced severe adverse cutaneous drug reaction among Asians, a review, Neurol Asia, 13, 15
- US Food & Drug Administration, 2017, Drugs
- Sanjuan-Jimenez, 2017, Prevalence of hepatitis E markers in Spanish patients with suspected drug-induced liver injury [abstract], Hepatology, 66, 423A
- Fernández-Castañer, 2008, An analysis of the causes, characteristics, and consequences of reexposure to a drug or compound responsible for a hepatotoxicity event, Rev Esp Enfermedades Dig, 100, 278
Cited by
Sorted by citations
Items 1,001–1,100 of 1,278
Gómez, M. L., Conde, M. H., Izquierdo, E. C. A., & Panero, J. L. C. (2024) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2024.05.021
Protocolo diagnóstico de la fiebre con hipertransaminasemia en el paciente inmunocomprometido
Izquierdo, E. C. A., Cao, J., Gómez, M. L., & Panero, J. L. C. (2024) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2024.05.024
Protocolo diagnóstico de la fiebre y la hipertransaminasemia en el paciente inmunocompetente
Izquierdo, E. C. A., Cao, J., Gómez, M. L., & Panero, J. L. C. (2024) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2024.05.023
Severe hepatic cholestasis after treatment with amoxicillin/clavulanic acid
Meier, M., & Eriksen, P. L. (2024) · Ugeskrift for Læger · doi:10.61409/v02240094
Ren, Z., Peng, J., Yan, T., Chen, J., Zhu, N., & Li, G. (2024) · Hepatitis Monthly · doi:10.5812/hepatmon-146984
Intensivtherapie bei akutem und chronischem Leberversagen
Sarrazin, C., Schneider, M., Bechstein, W. O., & Zeuzem, S. (2024) · Springer Reference Medizin · doi:10.1007/978-3-662-68699-7_74
A challenging case of drug-induced cholestatic liver injury: How to approach?Preprint
Badwei, N. (2024) · Research Square · doi:10.21203/rs.3.rs-4831502/v1
Edoxaban-Induced Vanishing Bile Duct Syndrome: A Case Report With Review of the Literature
Borgonovo, E., de Cristofaro, J., Aletti, F., Pedica, F., & D’Alessio, A. (2024) · Cureus · doi:10.7759/cureus.68071
Biomimetic injectable hydrogels of gelatin and hyaluronic acid for hepatic cell culture
Rodríguez-Fernández, J. (2024) · RiuNet (Universitat Politècnica de València) · doi:10.4995/thesis/10251/207128
Differenzialdiagnostisches Vorgehen bei Lebererkrankungen
Krämer, L., & Sarrazin, C. (2024) · Gastroenterologie up2date · doi:10.1055/a-2139-6541
A Helpful Bug in the System: Gut Microbes and Their Positive Impact on Portal Pressure Modulation
Hilscher, M. B. (2024) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2024.101399
Hu, R., Shen, J., Jiang, A., Lin, A., He, Y.-Y., Zhang, N., Cheng, Q., Liu, Z., Zhang, J., & Luo, P. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4967199
Ictericia sostenida tras colangiopancreatografía retrógrada endoscópica
Beraza, I. A., Carnerero, E. L., Martín, J. M. S., & Vigo, R. M. V. (2024) · Gastroenterología y Hepatología · doi:10.1016/j.gastrohep.2024.502264
An Updated Review on Fabrication and Characterization of Hepatoprotective Nanoparticles
Dandgavhal, B. G., Kakad, S. P., Kshirsagar, S. J., & Pawar, S. S. (2024) · Research Journal of Pharmaceutical Dosage Forms and Technology · doi:10.52711/0975-4377.2024.00043
Le risque iatrogène médicamenteux chez le sujet âgé
Chadli, Z., Kasraoui, K., Hannachi, I., Chaabane, A., Klii, R., Romdhane, H. B., Boughattas, N. A., Fredj, N. B., & Aouam, K. (2024) · La Tunisie Médicale · doi:10.62438/tunismed.v102i10.4970
Guermazi, F., Jbir, R., Bouaziz, I., Atheymen, R., Mnif, D., Ali, N. B., Ksouda, K., Zghal, K., Baati, I., & Masmoudi, J. (2024) · Therapies · doi:10.1016/j.therap.2024.11.004
МОТИВАЦИЯ ШКОЛЬНИКОВ-СПОРТСМЕНОВ В КОНТЕКСТЕ СТИЛЯ СЕМЕЙНЫХ ВЗАИМООТНОШЕНИЙ
Киселева, Н. Н., & Цветкова, Н. А. (2024) · Высшая школа: научные исследования · doi:10.34660/inf.2023.65.93.176
Primary Iliopsoas Abscess and Drug-Induced Liver Injury in the Emergency Department: A Case Report
Mederle, O. A., Sima, L., Popa, D. I., Williams, C. G., Mîțu, D.-A., Șutoi, D., Trebuian, C. I., Șelaru, M., Loloş, D., Pah, A.-M., et al. (2024) · Diseases · doi:10.3390/diseases12120326
Silalahi, C., Samosir, S. M., Prihaningtyas, R. A., Gunawan, P. I., & Setyoboedi, B. (2024) · Romanian Journal of Neurology · doi:10.37897/rjn.2024.4.1
Dwicahya, F., & Kholili, U. (2024) · The Indonesian Journal of Gastroenterology Hepatology and Digestive Endoscopy · doi:10.24871/253202462-69
Harikrishnan, S., G, G. K. C., Asokan, A., John, N. C., Sreehari, S., Nair, A. R., Parvathy, R., & Eapen, A. C. (2024) · Indian Journal of Critical Care Case Report · doi:10.5005/jp-journals-11006-0149
Ma, X., Lixia, Y., Xiangyu, Z., & Wanting, L. (2024) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000002126
Leyva-López, Y., Rivera‐Buendía, F., & Ortega‐Zhindón, D. B. (2025) · Cirugía Cardiaca en México · doi:10.35366/118935
Ганцгорн, Е. В., Bozhko, A. V., & Yarchenko, S. V. (2025) · Safety and Risk of Pharmacotherapy · doi:10.30895/2312-7821-2025-447
Jing, Y., Jing, J., Sun, X., Jin, Y. X., & Bai, X. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1537688
Hepatitis autoinmunes, metabólicas y otras hepatitis no infecciosas
Díez, M. A., & Remacha, E. F. (2025) · Pediatría Integral · doi:10.63149/j.pedint.6
Hussaini, H., Waheed, A., Fadeyi, O. A., Boostany, T., Hashimoto, Y., & Flint, A. T. (2025) · Cureus · doi:10.7759/cureus.79839
Yang, J., Luo, W. P., Chen, Y., Zhou, Y., Wang, J., Mi, L., & Shi, G. (2025) · Life Sciences · doi:10.1016/j.lfs.2025.123526
Clinical case of death of a patient with anti-tuberculosis drug-induced liver damage
Abasova, A. S., Kurbanova, T. M., & Abasov, A. R. (2025) · Spravočnik vrača obŝej praktiki (Journal of Family Medicine) · doi:10.33920/med-10-2502-06
Squires, R., Blair, C., Karteszi, H., Modarres, P., Caws, C., Mookherjee, S., Robinson, T., & Abeysekera, K. W. M. (2025) · eGastroenterology · doi:10.1136/egastro-2024-100157
Precise subcellular organelle-targeted analyses of hepatotoxicity of Polygonum multiflorum
Li, Y., Duan, S., Zhang, Y., Liu, R., Sun, R., Wu, J., Ma, Z., & Li, X. (2025) · Chinese Herbal Medicines · doi:10.1016/j.chmed.2025.03.001
Research Progress on the Etiology of Cholestatic Liver Disease in School-Age Children
李, 小. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.1541133
Béquignon, O. J. M., Wink, S., Hiemstra, S. W., Fokkelman-Klip, J. E., den Hollander, W., Callegaro, G., van de Water, B., & van Westen, G. J. P. (2025) · ChemRxiv · doi:10.26434/chemrxiv-2025-xdc1q
Béquignon, O. J. M., Wink, S., Hiemstra, S. W., Fokkelman-Klip, J. E., den Hollander, W., Callegaro, G., van de Water, B., & van Westen, G. J. P. (2025) · ChemRxiv · doi:10.26434/chemrxiv-2025-xdc1q-v2
Sustained jaundice after endoscopic retrograde cholangiopancreatography
Beraza, I. A., Carnerero, E. L., Martín, J. M. S., & Vigo, R. M. V. (2025) · Gastroenterología y Hepatología (English Edition) · doi:10.1016/j.gastre.2025.502264
Hanifa, A. M., Saifudeen, S. F., Murugesan, H., Sivadasan, S., & Murugesan, K. (2025) · Saudi Journal of Medical and Pharmaceutical Sciences · doi:10.36348/sjmps.2025.v11i04.017
Wang, Y., Li, G., Du, J., Wang, F., Meng, Y., Zhang, Z., & Wang, W. (2025) · Research Square · doi:10.21203/rs.3.rs-6694007/v1
Autoimmune Hepatitis and Drug-Induced Liver Injury in Japan
Nishikawa, H., Kim, S. K., & Asai, A. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14134514
Kumar, B., & Disha, N. S. (2025) · Annals of Phytomedicine An International Journal · doi:10.54085/ap.2025.14.1.8
Fu, L., Zhang, L., Huo, G., Qiu, J., Qiao, F., Huang, L., Zhu, X., Yu, Z., Tang, Y., Wu, M., et al. (2025) · Journal of Proteomics · doi:10.1016/j.jprot.2025.105490
Talab, T. J., Shafi, F. A. A., & Jasim, S. M. (2025) · World Academy of Sciences Journal · doi:10.3892/wasj.2025.377
TAN, J., Zhou, P. Y., Lim, J. L., Liu, F., & Kwa, L. H. A. (2025) · Antibiotics · doi:10.3390/antibiotics14080758
Management of asymptomatic patients with abnormal liver function tests
Gabeta, S., Dalekos, G. Ν., & Gatselis, N. (2025) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2025.07.025
Wang, Y., Sun, Z., Lin, Y., Tao, M., Zhao, W., Liu, J., Guo, X., Hang, C., Wang, M., Tan, W., et al. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1603543
Zhang, L., Ren, Y., Su, D., Jiang, Q., Peng, H., Cheng, F., Zhang, H., Bai, X. L., Wei, X., Yang, W., et al. (2025) · MedComm · doi:10.1002/mco2.70339
Fu, H., Song, S., Zhao, H., Du, B., Chen, Y., Xiao, Y., Zang, X., Lai, R., Mo, R., Huang, Y., et al. (2025) · Postgraduate Medical Journal · doi:10.1093/postmj/qgaf142
P19-34 Ontogeny of Drug-Induced Steatosis: From Key Initiating Events to Disease Phenotypes
López-Pascual, E., Moreno‐Torres, M., Moro, E., Soluyanova, P., Rapisarda, A. S., Ortega-Vallbona, R., Serrano‐Candelas, E., Gozalbes, R., Jover, R., & Castell, J. V. (2025) · Toxicology Letters · doi:10.1016/j.toxlet.2025.07.591
Serras, A. S., Camões, S. P., Vej-Nielsen, J. M., Vitorino, R. M. P., & Miranda, J. P. (2025) · Toxicology Letters · doi:10.1016/j.toxlet.2025.07.590
A Rare Case of Drug-Induced Liver Injury Due to Metformin and Literature Review
刘, 清. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.1592514
Reimann, H. (2025) · Journal of Consumer Protection and Food Safety · doi:10.1007/s00003-025-01570-8
Tan, S., Yang, Y., Cai, Y., Pu, Y., Gu, Z., & Zhang, J. (2025) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2025.117576
Impaired Liver Function in the Use of Clozapine as an Antipsychotic
Aziz, A., Herawati, F., Pratama, J. E., & Gondokesumo, M. E. (2025) · Journal of Food and Pharmaceutical Sciences · doi:10.22146/jfps.20811
Larrey, D. G., Zhou, F. L., Brulle-Wohlhueter, C., Bénamor, M., Chavin, J. M., Razaz, N., Bejuit, R., Dauriat, J., Reppelin, T., Péan, R., et al. (2025) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2025.106785
Self-citationFaktor-faktor yang Berhubungan dengan Kepatuhan Pelaksanaan Monitoring Early Warning Score (EWS)
Wulandari, E., Gaghauna, E. E. M., Redjeki, D. S. S., & Riduansyah, M. (2025) · Journal of Language and Health · doi:10.37287/jlh.v6i3.283
Risk of liver dysfunction with ACE inhibitors based on real-world data from the MID-NET® in Japan
Kinoshita, Y., Ando, T., Kajiyama, K., Maruyama, H., Kohama, M., Tanaka, A., Matsunaga, Y., Ishiguro, C., Nonaka, T., Horiuchi, N., et al. (2025) · Hypertension Research · doi:10.1038/s41440-025-02390-x
Overestimating the risk of febuxostat's hepatotoxicity? comment on the article by Sun et al
Gadekallu, S. H. R. (2025) · Arthritis Care & Research · doi:10.1002/acr.25663
Acute liver failure caused by alkaloids from traditional Chinese medicine: A case report
Zhu, X.-Y., Zhao, Y.-T., Su, C.-S., Yuan, X., Zhang, S., & Nashan, B. (2025) · World Journal of Hepatology · doi:10.4254/wjh.v17.i10.109575
A Rare Case of Isolated Raised Gamma-Glutamyl Transferase Secondary to Rifampicin
Mohanan, K., Choudhary, R., Sharma, N. K., & Sharma, A. (2025) · The Journal of Association of Chest Physicians · doi:10.4103/jacp.jacp_12_25
Wang, K., Meng, Q., & Hou, W. (2025) · Hepatitis Monthly · doi:10.5812/hepatmon-165001
Khalil, M. I., Fatima, K. B., & Zafar, A. (2025) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70402
A case report of tumor-associated liver injury alleviated with antineoplastic drug
Yang, Z., Cao, L., Kuai, W., Yao, S., Li, S., & Xu, L. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1644790
Liu, W., Zhang, Z., Ma, X., Zeng, X., Yuan, S., Li, X., Nie, F., & Yang, L. (2025) · Medicine · doi:10.1097/md.0000000000045750
Contemporary perspective and practical application of glutamate dehydrogenase in nonclinical studies
Ravindra, K. C., Ameri, M., Baker, K. S., Faber, S. C., Rovira, A. R. I., Jackson, J. P., Norona, L. M., Proctor, W. R., Rae, J. M. C., Regev, A., et al. (2025) · Biomarkers in Medicine · doi:10.1080/17520363.2025.2595911
Zhang, T., Li, M., Ge, Y., Teng, X., Zhao, H., Wang, H., Zhou, X., & Xie, W. (2025) · npj gut and liver. · doi:10.1038/s44355-025-00027-x
Rachynska, I., & Хухліна, О. (2025) · Перспективи та інновації науки · doi:10.52058/2786-4952-2025-11(57)-3570-3584
Derymedvid, L. V., & Petroshchuk, S. R. (2025) · Likarska sprava · doi:10.31640/ls-2025-4-18
Gastroenterolojide Sık Konsültasyonlar
Ecemiş, Ö., & Tuncel, E. T. (2025) · Akademisyen Kitabevi eBooks · doi:10.37609/akya.3785.c461
Watanabe, S., Wada, Y., Nagata, J., Asakawa, T., Hirata, K., & Fujino, Y. (2025) · BMC Complementary Medicine and Therapies · doi:10.1186/s12906-025-05186-1
Certolizumab-associated autoimmune-like hepatitis
Peggie, E., Shetty, S., Johnston, M., May, C., Oien, K., & Kohnen, G. (2025) · BMJ Case Reports · doi:10.1136/bcr-2025-266955
Development of an in vitro test battery for a test system to predict human drug-induced liver injury
Brecklinghaus, T. (2021) · Technische Universität Dortmund Eldorado (Technische Universität Dortmund) · doi:10.17877/de290r-22564
Albrecht, W. (2021) · Technische Universität Dortmund Eldorado (Technische Universität Dortmund) · doi:10.17877/de290r-22163
A Rare Case of Dapagliflozin-Induced Hepatic Toxicity
Fernandes, C., & Torres-Ramalho, P. (2023) · Medicina Interna · doi:10.24950/rspmi.2520
Implementing pharmacokinetic guided dosing to support the safe use of tyrosine kinase inhibitors
Westerdijk, K. (2025) · Radboud Repository (Radboud University)
Applied medical informatics : AMI
(n.d.) · RWTH Publications (RWTH Aachen)
A Rare Case of Dapagliflozin-Induced Hepatic Toxicity
Fernandes, C. B., & Ramalho, P. T. (2024) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Gaihre, M., Jha, S., Pathak, R., Ghimire, S., Baranawal, P., Poudel, A., & Bhatta, R. (2025) · Medical Reports · doi:10.1016/j.hmedic.2025.100374
Autoimmune Hepatitis and Overlapping Syndrome
Liang, Y., & Zhang, X. (2025) · Pracatical anatomic pathology · doi:10.1007/978-3-031-97506-6_11
ЛЕКАРСТВЕННО-АССОЦИИРОВАННАЯ ЖИРОВАЯ БОЛЕЗНЬ ПЕЧЕНИ
П., П. А., & Д., О. О. (n.d.) · CyberLeninK (CyberLeninka)
DRUG-INDUCED LIVER TOXICITY: MECHANISMS AND THERAPEUTIC TARGETS
Manna, S., Sarkar, S., Saha, N. C., & Banerjee, P. (2025) · doi:10.65525/svup.9788198800473.2025.199-208
Tocotrienol as a Potential Treatment for Drug-Induced Liver Injury
Norman, N. S. S. M., Ruslan, M. R. A. R. B., Hamid, J. A., Sidik, F. Z. J., Azlina, M. F. N., & Abdullah, A. (2025) · International Journal of Pharmacology · doi:10.31083/ijp44046
Refractory autoimmune hepatitis in children: Considerations for assessment and management
Valamparampil, J. J., Brown, R. M., & McKiernan, P. J. (2025) · World Journal of Hepatology · doi:10.4254/wjh.v17.i12.110966
Akbulut, M., Tan, S., Çetin, H., & Özdamar, S. (2025) · Sağlık Bilimleri Dergisi · doi:10.34108/eujhs.1671907
Wei, X., Huang, L., & Li, X. (2026) · Gynecological Endocrinology · doi:10.1080/09513590.2025.2612154
Redox-dependent substrate use in hepatic gluconeogenesis shapes exercise performance
Luukkonen, P. K. (2026) · Journal of Hepatology · doi:10.1016/j.jhep.2025.12.008
Bessone, F., & Hernández, N. (2026) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2025.00450
Rahayu, F. K., Cahyani, A. N., Prayogi, S., Anggraeni, D. S., Zahra, P. A., Ernanda, A. R., Falupi, I. F., & Rahma, D. R. (2025) · MEDFARM Jurnal Farmasi dan Kesehatan · doi:10.48191/medfarm.v14i2.678
Arslan, M. (2026) · Turkish Journal of Pediatric Disease · doi:10.12956/tjpd.2025.1226
Chen, T., Yang, Y.-R., He, M.-H., Zhang, X., Liao, S., Zeng, Z., Long, Y.-G., Lin, Y. J., & Tu, B. (2026) · Fitoterapia · doi:10.1016/j.fitote.2026.107096
Herb-Induced Liver Injury by Laurus nobilis: A Case Assessed for Causality Using the Updated RUCAM
Soare, M., Călugăr-Șolea, S.-F., Brisc, C., Rus, M., Bodog, T. M., Becheanu, G., Brisc, C. M., & Brisc, M. C. (2026) · Life · doi:10.3390/life16010180
He, Z., Luo, Z., Dai, P., Wang, X., & Yang, J. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105153
Abnormalities of liver function during critical illness
Meersseman, P., Wilmer, A., & Langouche, L. (2026) · Current Opinion in Critical Care · doi:10.1097/mcc.0000000000001362
Late hepatotoxicity after treatment for childhood cancer
Roganović, J., Vidović, A., & Đordević, A. (2026) · World Journal of Hepatology · doi:10.4254/wjh.v18.i1.113465
Adiwinata, R., Tanadi, C., Pajala, F. B., Tandarto, K., Stella, M. M., Tenggara, J. B., Gunarsa, R. G., Simadibrata, P., Siregar, L., Nababan, S., et al. (2026) · Rambam Maimonides Medical Journal · doi:10.5041/rmmj.10571
Clinical management of hypersensitivity reactions to antituberculosis drugs
Park, S. S., & Kang, H. (2026) · Allergy Asthma & Respiratory Disease · doi:10.4168/aard.2026.14.1.4
Gao, J., Zhu, Y., Gong, Y., Song, L., Wu, Z., Shi, J., Liu, L., & Yao, Q. (2026) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkag032
Kumari, K., & Baligar, P. (2025) · Biointerface Research in Applied Chemistry · doi:10.33263/briac156.090
Wang, S., Wang, N., Qian, Z., Xu, C., Wang, X., Ayaka, T., Zhu, Z., Xie, X., & Yu, L. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5331045
Metadata
- Authors
- Andrade, R. J., Aithal, G. P., Björnsson, E. S., Kaplowitz, N., Kullak-Ublick, G. A., Larrey, D., & Karlsen, T. H.
- ORCID
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2019-06
- Volume
- 70
- Issue
- 6
- Pages
- 1222-1261
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W2924328881
- Semantic Scholar
- 6d774d1c570eef200451a1e8a8f5655c367a4eaf
- Cited by
- 1,276
- References
- 371
- Citations by year
- 2026: 243 · 2025: 211 · 2024: 175 · 2023: 159 · 2022: 158 · 2021: 184 · 2020: 117 · 2019: 27
- FWCI
- 78.91
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Hepatology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- European Cooperation in Science & Technology
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- drug-induced liver injury, idiosyncratic drug-induced liver injury, hepatotoxicity, acute liver failure, risk factors, diagnosis, risk minimization
- MeSH terms
- Adult, Aged, Fatty Liver, Female, Histocompatibility Testing, Humans, Liver Neoplasms, Male, Middle Aged, Mitochondria, Risk Factors, Chemical and Drug Induced Liver Injury
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
